Advisory Committee on Breast Cancer in Young Women (ACBCYW); Cancellation of Meeting, 25452 [2020-09305]
Download as PDF
<![CDATA[
25452
Federal Register / Vol. 85, No. 85 / Friday, May 1, 2020 / Notices
(HAMP) Workgroup, NIOSH Miner
Health Program strategic plan, NIOSH
Mining respirable crystalline silica
research, Understanding elongate
mineral particle exposure in mining,
Research roadmap for haul truck health
and safety issues, and Future of the coal
industry presentation. The meeting will
also include an update from the NIOSH
Associate Director for Mining. Agenda
items are subject to change as priorities
dictate.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2020–09306 Filed 4–30–20; 8:45 am]
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
Advisory Committee on Breast Cancer
in Young Women (ACBCYW);
Cancellation of Meeting
Notice is hereby given of a change in
the meeting of the Advisory Committee
on Breast Cancer in Young Women
(ACBCYW); May 13, 2020, 8:00 a.m. to
1:00 p.m., EDT.
The teleconference and web
conference, which was published in the
Federal Register on March 16, 2020,
Volume 85, Number 51, page 14945, is
being canceled in its entirety.
FOR FURTHER INFORMATION CONTACT:
Jeremy McCallister, Designated Federal
Officer, National Center for Chronic
Disease Prevention and Health
Promotion, CDC, 4770 Buford Hwy. NE,
Mailstop S107–4, Atlanta, Georgia
30341, Telephone (404) 639–7989, Fax
(770) 488–4760; Email: acbcyw@
cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
08:07 May 01, 2020
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2020–09305 Filed 4–30–20; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2019–0069]
Proposed Update of the CDC’s 2006
Revised Recommendations for HIV
Testing of Adults, Adolescents, and
Pregnant Women in Health-Care
Settings; Re-opening of the Comment
Period
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Disease
Control and Prevention (CDC) in the
Department of Health and Human
Services (HHS) announces the reopening of this docket to obtain
additional public comment on the
proposed update of the 2006 Revised
Recommendations for HIV Testing. CDC
is re-opening this docket at the request
of the public.
DATES: Electronic or written comments
must be received by June 30, 2020.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2019–
0069, by any of the following methods
below. CDC does not accept public
comment by email.
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: DHAP Guideline Team,
Centers for Disease Control and
Prevention, 1600 Clifton Road, NE, MS
US8–4, Atlanta, Georgia 30329.
FOR FURTHER INFORMATION CONTACT:
Priya Jakhmola, Health Scientist,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
US8–4, Atlanta, Georgia 30329.
Telephone: 404–639–2495, Email:
dhapguideline@cdc.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
VerDate Sep<11>2014
Prevention and the Agency for Toxic
Substances and Disease Registry.
Jkt 250001
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data related to HIV screening
approaches. In addition, CDC invites
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
comments specifically on opt-out
routine HIV testing, including, but not
limited to:
• Suggestions for revisions, edits, and
new additions
• Contemporary issues and new
evidence
• Implementation barriers, challenges,
and lessons learned
• Examples of innovative models,
partnerships, and collaborations
Please note that comments received,
including attachments and other
supporting materials, are part of the
public record and are subject to public
disclosure. Comments will be posted on
https://www.regulations.gov. Therefore,
do not include any information in your
comments or supporting materials that
you consider confidential or
inappropriate for public disclosure. If
you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be on
public display. CDC will review all
submissions and may choose to redact,
or withhold, submissions containing
private or proprietary information,
inappropriate language, or examples of
a mass-mail campaign. CDC will
carefully consider all comments
submitted in preparation of the final
document and may revise the final
document as appropriate.
Background
On August 30, 2019, CDC published
a notice (84 FR 45495) announcing the
availability of a Proposed Update of the
CDC’s 2006 Revised Recommendations
for HIV Testing of Adults, Adolescents,
and Pregnant Women in Health-Care
Settings. The comment period ended
October 28, 2019. CDC received a
request from the public to re-open the
comment period.
The CDC guideline ‘‘Revised
Recommendations for HIV Testing of
Adults, Adolescents, and Pregnant
Women in Health-Care Settings’’ was
published on September 22, 2006 in
CDC’s Morbidity and Mortality Weekly
Report (MMWR). Since then, there have
been changes in evidence related to HIV
testing technologies and interventions,
disease epidemiology, outcomes,
implementation resources, and related
guidelines. This evidence will be
identified, assessed, and analyzed to
inform the update of the guideline.
CDC will update the 2006 guideline
based on input from subject matter
experts, public health agencies, the
public, and other stakeholders. The
guideline development process will
draw on up-to-date nationally and
internationally accepted guideline
E:\FR\FM\01MYN1.SGM
01MYN1
]]>Agencies
[Federal Register Volume 85, Number 85 (Friday, May 1, 2020)]
[Notices]
[Page 25452]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-09305]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Advisory Committee on Breast Cancer in Young Women (ACBCYW);
Cancellation of Meeting
Notice is hereby given of a change in the meeting of the Advisory
Committee on Breast Cancer in Young Women (ACBCYW); May 13, 2020, 8:00
a.m. to 1:00 p.m., EDT.
The teleconference and web conference, which was published in the
Federal Register on March 16, 2020, Volume 85, Number 51, page 14945,
is being canceled in its entirety.
FOR FURTHER INFORMATION CONTACT: Jeremy McCallister, Designated Federal
Officer, National Center for Chronic Disease Prevention and Health
Promotion, CDC, 4770 Buford Hwy. NE, Mailstop S107-4, Atlanta, Georgia
30341, Telephone (404) 639-7989, Fax (770) 488-4760; Email:
[email protected].
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2020-09305 Filed 4-30-20; 8:45 am]
BILLING CODE 4163-18-P
